Structure-kinetic relationship study of CDK8/CycC specific compounds

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 20, 2013, Pages 8081-8086

  Schneider, Elisabeth V ^a,b   Böttcher, Jark ^b   Huber, Robert ^a,c,d,e   Maskos, Klaus ^b   Neumann, Lars ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b PROTEROS BIOSTRUCTURES GMBH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Kinetic profiling; Structure based drug design

Indexed keywords

CYCLIN C; CYCLIN DEPENDENT KINASE 8;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; ENZYME BINDING; ENZYME KINETICS; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; TIME; VELOCITY;

KINETIC PROFILING; STRUCTURE-BASED DRUG DESIGN;

AMINO ACID MOTIFS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYCLIN C; CYCLIN-DEPENDENT KINASE 8; DRUG DESIGN; HUMANS; HYDROGEN BONDING; KINETICS; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; SALTS; TEMPERATURE; TIME FACTORS;

EID: 84877853315     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1305378110     Document Type: Article

References (46)

1. Firestein R, et al. (2008) CDK8 is a colorectal cancer oncogene that regulates betacatenin activity. Nature 455(7212):547-551.
2. Firestein R, Hahn WC (2009) Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Res 69(20):7899-7901.
3. Morris EJ, et al. (2008) E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature 455(7212):552-556.
4. He S-B, et al. (2011) Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. J Exp Clin Cancer Res 30:109.
5. Pinhero R, Liaw P, Bertens K, Yankulov K (2004) Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II. Eur J Biochem 271(5):1004-1014. (Pubitemid 38299654)
6. Hengartner CJ, et al. (1998) Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases. Mol Cell 2(1):43-53. (Pubitemid 128378965)
7. Akoulitchev S, Chuikov S, Reinberg D (2000) TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 407(6800):102-106.
8. Donner AJ, Szostek S, Hoover JM, Espinosa JM (2007) CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell 27(1):121-133. (Pubitemid 46991381)
9. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM (2010) CDK8 is a positive regulator of transcriptional elongation within the serum responsenetwork. Nat Struct Mol Biol 17(2):194-201.
10. Galbraith MD, Donner AJ, Espinosa JM (2010) CDK8: A positive regulator of transcription. Transcription 1(1):4-12.
11. Kapoor A, et al. (2010) The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468(7327):1105-1109.
12. Dietrich J, Hulme C, Hurley LH (2010) The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. Bioorg Med Chem 18(15):5738-5748.
13. Backes AC, Zech B, Felber B, Klebl B, Müller G (2008) Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 3(12):1427-1449.
14. Zuccotto F, Ardini E, Casale E, Angiolini M (2010) Through the "gatekeeper door": Exploiting the active kinase conformation. J Med Chem 53(7):2681-2694.
15. Kroe RR, et al. (2003) Thermal denaturation: A method to rank slow binding, highaffinity P38alpha MAP kinase inhibitors. J Med Chem 46(22):4669-4675. (Pubitemid 37271616)
16. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5(9):730-739. (Pubitemid 44323700)
17. Tummino PJ, Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47(20):5481-5492. (Pubitemid 351711169)
18. Müller G, Sennhenn PC, Woodcock T, Neumann L (2010) The 'retro-design' concept for novel kinase inhibitors. IDrugs 13(7):457-466.
19. Lu H, Tonge PJ (2010) Drug-target residence time: Critical information for lead optimization. Curr Opin Chem Biol 14(4):467-474.
20. Huber R, et al. (1974) Structure of the complex formed by bovine trypsin and bovine pancreatic trypsin inhibitor. II. Crystallographic refinement at 1.9 A resolution. J Mol Biol 89(1):73-101.
21. Neumann L, Ritscher A, Müller G, Hafenbradl D (2009) Fragment-based lead generation: Identification of seed fragments by a highly efficient fragment screening technology. J Comput Aided Mol Des 23(8):501-511.
22. Neumann L, von König K, Ullmann D (2011) HTS reporter displacement assay for fragment screening and fragment evolution toward leads with optimized binding kinetics, binding selectivity, and thermodynamic signature. Methods Enzymol 493:299-320.
23. Schneider EV, et al. (2011) The structure of CDK8/CycC implicates specificity in the CDK/ cyclin family and reveals interaction with a deep pocket binder. J Mol Biol 412(2):251-266.
24. Echalier A, Endicott JA, Noble ME (2010) Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta 1804(3):511-519.
25. Pargellis C, et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9(4):268-272. (Pubitemid 34289898)
26. Simard JR, et al. (2009) Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J Am Chem Soc 131(37):13286-13296.
27. Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2(7):358-364. (Pubitemid 43936934)
28. Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R (1993) Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J 12(3):849-859. (Pubitemid 23095833)
29. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109(3): 275-282. (Pubitemid 34606870)
30. Lo Conte L, Chothia C, Janin J (1999) The atomic structure of protein-protein recognition sites. J Mol Biol 285(5):2177-2198. (Pubitemid 29078179)
31. Regan J, et al. (2003) Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2- morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796). J Med Chem 46(22):4676-4686. (Pubitemid 37271617)
32. Schmidtke P, Luque FJ, Murray JB, Barril X (2011) Shielded hydrogen bonds as structural determinants of binding kinetics: Application in drug design. J Am Chem Soc 133(46):18903-18910.
33. Jeffrey PD, et al. (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376(6538):313-320.
34. Pavletich NP (1999) Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287(5):821-828. (Pubitemid 29188868)
35. Holdgate GA, Gill AL (2011) Kinetic efficiency: The missing metric for enhancing compound quality? Drug Discov Today 16(21-22):910-913.
36. Lolli G (2010) Structural dissection of cyclin dependent kinases regulation and protein recognition properties. Cell Cycle 9(8):1551-1561.
37. Baumli S, Endicott JA, Johnson LN (2010) Halogen bonds form the basis for selective P-TEFb inhibition by DRB. Chem Biol 17(9):931-936.
38. Kornev AP, Haste NM, Taylor SS, Eyck LF (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103(47):17783-17788. (Pubitemid 44852237)
39. Noble M, et al. (2005) Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochim Biophys Acta 1754(1-2):58-64. (Pubitemid 41797687)
40. Otyepka M, Kríz Z, Koca J (2002) Dynamics and binding modes of free cdk2 and its two complexes with inhibitors studied by computer simulations. J Biomol Struct Dyn 20(2):141-154. (Pubitemid 35265924)
41. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66(Pt 2):125-132.
42. Dodson EJ, Winn M, Ralph A (1997) Collaborative Computational Project, number 4: Providing programs for protein crystallography. Methods Enzymol 277:620-633. (Pubitemid 27390943)
43. Vagin A, Teplyakov A (2010) Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 66(Pt 1):22-25.
44. Vagin AA, et al. (2004) REFMAC5 dictionary: Organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2184-2195. (Pubitemid 41742770)
45. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132. (Pubitemid 41742764)
46. The PyMOL Molecular Graphics System (Schrödinger, New York), Version 1.2.